CLINICAL TRIAL SUMMARY

MDACC Study No:2006-0873 (clinicaltrials.gov NCT No: NCT00523809)
Title:Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation with Bevacizumab for Advanced Solid Tumor
Principal Investigator:Naoto Ueno
Treatment Agent:Bevacizumab; Fludarabine; Melphalan
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if giving Avastin
(bevacizumab) with standard chemotherapy and a blood stem cell transplant, in
patients with an advanced solid tumor, can help to shrink the tumor or slow its
growth. The safety of this treatment will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Breast; Kidney; Ovary
Phase of Study:Phase II
Treatment Agents:Bevacizumab
Fludarabine
Melphalan
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Per BMT standard. 3-4 weeks as inpatient & 100 days stay at Houston after the
day of transplant.
Supported By:N/A
Return Visit:Per BMT standard. At least twice a week.
Home Care:No.


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Naoto Ueno
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8754
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults